AB Science Granted Patent for Masitinib in COVID-19 Treatment Until 2041

AB Science, a pharmaceutical company specializing in the research and development of protein kinase inhibitors (PKIs), recently announced positive developments regarding its lead compound, masitinib. This molecule has demonstrated potential in treating various diseases, including viral infections like COVID-19. The company's efforts have been recognized with a new patent granted by the Chinese Patent Office, securing intellectual property protection for masitinib in the treatment of SARS-CoV-2 infection until April 2041.

Masitinib Shows Promise in Combating Viral Diseases

The patent stems from preclinical data published in the esteemed journal Science, highlighting masitinib's broad antiviral activity. Studies revealed its effectiveness against SARS-CoV-2, including in vivo activity in mice and maintained efficacy in vitro against variants of concern. This preclinical data provides a strong foundation for further research and development.

Positive Results from Clinical Trials

Adding to the encouraging findings, AB Science recently reported positive results from its phase 2 study evaluating masitinib in COVID-19 patients. Professor Olivier Hermine, MD, President of the Scientific Committee of AB Science, emphasized the anti-inflammatory activity of masitinib in controlling activated macrophages and mast cells involved in the disease. Furthermore, he underscored several publications that demonstrated masitinib's capacity to act as an indirect broad antiviral agent against COVID-19.

These positive results from clinical trials solidify the potential of masitinib as a promising therapeutic option for COVID-19. Professor Hermine's statement reflects the growing recognition of masitinib's ability to be considered a drug of choice in future pandemic scenarios.

Masitinib Protection and Future Directions

The newly granted patent, extending intellectual property protection for masitinib protection until April 2041, signifies AB Science's commitment to advancing research and development in this crucial area. This patent provides a strong legal framework for commercializing masitinib as a treatment for COVID-19, ensuring the company can continue to invest in bringing this potentially life-saving drug to patients worldwide.

Looking ahead, AB Science plans to build upon these promising results by conducting further research and exploring the potential applications of masitinib in other viral diseases. The company's focus on developing targeted therapies with high unmet medical needs positions it at the forefront of innovation in the pharmaceutical industry.

The combination of robust preclinical data, positive clinical trial outcomes, and strong intellectual property protection lays a solid foundation for AB Science's continued success in bringing innovative treatments to market. The potential of masitinib to address pressing global health challenges, particularly in the realm of viral diseases, underscores its significance in the fight against emerging infectious threats.